The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.

Jie YuArianne N SweetingChris GianacasLauren HoustonVivian LeeRobert A FletcherVlado PerkovicQiang LiBrendon L NeuenOtavio BerwangerHiddo J Lambers HeerspinkDick de ZeeuwClare Arnott

Published in: Diabetes, obesity & metabolism (2023)

The cardiovascular and renal benefits of canagliflozin and its safety profile were consistent across population-specific BMI subgroups for adults in the CANVAS Program and CREDENCE trial.

Keyphrases

body mass index
type diabetes
study protocol
phase iii
quality improvement
phase ii
weight gain
physical activity
cardiovascular disease
open label
glycemic control